Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial. J of Skin [Internet]. 2022 Nov. 16 [cited 2026 Apr. 19];6(6):s47. Available from: https://skin.dermsquared.com/skin/article/view/1802